drugset / Trial / NCT06108219

A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH)

NCT06108219

Phase 2 Active not recruiting 175 enrolled Corcept Therapeutics
RandomizedParallel-groupQuadruple-blindTreatment

Summary

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Miricorilant in Adult Patients with Nonalcoholic Steatohepatitis (MONARCH)

Timeline

Start
2023-10-25
Primary completion
2026-09
Completion
2026-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Miricorilant Small molecule 100 mg Oral
Subject Miricorilant Small molecule 200 mg Oral